Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer

被引:91
作者
Krähn, G
Leiter, U
Kaskel, P
Udart, M
Utikal, J
Bezold, G
Peter, RU
机构
[1] Univ Ulm, Dept Dermatol, D-89081 Ulm, Germany
[2] Univ Munich, Dept Dermatol, D-8000 Munich, Germany
关键词
receptor tyrosine kinase; erbB; EGFR; HER2; HER3; HER4; basal cell carcinomas; squamous cell carcinomas; skin; rtPCR;
D O I
10.1016/S0959-8049(00)00364-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR), HER2, HER3 and HER4 are involved in the pathogenesis of multiple human malignant neoplasias. However, their role in the carcinogenesis of basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) remains to be elucidated. In order to further define the role of these RTKs, 56 human skin tissue samples of normal skin, BCC and SCC were studied by conventional and differential and quantitative reverse transcriptase-polymerase chain reaction (rtPCR). EGFR and HER3 were predominantly expressed in the BCCs and SCCs, while HER2 was ubiquitously expressed. HER4 was not expressed in any sample. Since in vitro studies have provided compelling evidence that heterodimer formation of these receptors are associated with different signal transduction processes, coexpression patterns might be decisive for the induction and maintenance of a malignant phenotype. These results confirm this concept: isolated HER2 expression and EGFR/HER2 were predominantly found in normal skin, while HER2/HER3 and the triple expression of EGFR/HER2/HER3 were seen more frequently in the BCCs and SCCs compared with normal skin (50% and 40% compared with 26%, respectively). The activation of HER3, in addition to EGFR and HER2, might therefore be associated with the malignant phenotype. However, due to the small numbers in this study, further confirmation of the patterns is needed. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:251 / 259
页数:9
相关论文
共 58 条
[1]   Increased level of c-erbB-2/neu/HER-2 protein in cutaneous squamous cell carcinoma [J].
Ahmed, NU ;
Ueda, M ;
Ichihashi, M .
BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (06) :908-912
[2]  
ALIMANDI M, 1995, ONCOGENE, V10, P1813
[3]  
Bacus SS, 1996, ONCOGENE, V12, P2535
[4]   EPIDERMAL GROWTH-FACTOR RECEPTORS IN DIFFERENT SKIN TUMORS [J].
BAUKNECHT, T ;
GROSS, G ;
HAGEDORN, M .
DERMATOLOGICA, 1985, 171 (01) :16-20
[5]  
Bodey B, 1997, ANTICANCER RES, V17, P1319
[6]   Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases [J].
Carraway, KL ;
Weber, JL ;
Unger, MJ ;
Ledesma, J ;
Yu, N ;
Gassmann, M ;
Lai, C .
NATURE, 1997, 387 (6632) :512-516
[7]  
DIACO R, 1995, PCR STRATEGIES, P84
[8]   CLOSE SIMILARITY OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND V-ERB-B ONCOGENE PROTEIN SEQUENCES [J].
DOWNWARD, J ;
YARDEN, Y ;
MAYES, E ;
SCRACE, G ;
TOTTY, N ;
STOCKWELL, P ;
ULLRICH, A ;
SCHLESSINGER, J ;
WATERFIELD, MD .
NATURE, 1984, 307 (5951) :521-527
[9]  
Drachenberg CB, 1997, CANCER DETECT PREV, V21, P483
[10]  
FRYE RA, 1989, ONCOGENE, V4, P1153